成纤维细胞活化蛋白
疤痕
医学
药品
生物标志物
CTGF公司
伤口愈合
成纤维细胞
结缔组织
癌症研究
病理
生长因子
药理学
免疫学
内科学
化学
体外
癌症
受体
生物化学
作者
David Yeo,Christian Wiraja,Qingqing Miao,Xiaoyu Ning,Kanyi Pu,Chenjie Xu
标识
DOI:10.1021/acsabm.8b00528
摘要
Abnormal scarring is a hyper-proliferative wound healing disorder, which causes itch, pain, psychological distress, and even limiting limb mobility. Unfortunately, no satisfactory treatment exists to date. Drug screening identifies suitable drugs or drug combinations that inhibit abnormal scarring from a large selection of candidates. However, current techniques are often laborious and technically complex. Herein, we adopt a near-infrared fluorescence probe (FNP1) for fibroblast activation protein (FAP)α, a biomarker overexpressed in skin fibroblasts derived from abnormal scars, to rapidly assess (<30 min) drug candidates for the treatment. FNP1 has high sensitivity, even detecting FAPα up-regulation with as little as 0.016 ng/mL TGFβ1, 125-fold lower than typical culture concentrations. The identified drug candidates (RepSox and Thiazovivin) show similar potent anti-scarring activity as the existing anti-scarring compounds and further suppress the expression of other scar biomarkers including connective tissue growth factor (CTGF), alpha-smooth muscle actin (α-SMA), and collagen type 1 (COL1A1).
科研通智能强力驱动
Strongly Powered by AbleSci AI